Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by ferraridanon Jan 17, 2020 9:23pm

109 Views

Post# 30567782

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:where is the great francine in all this

Scopro, yes that's my fear (again I hope I'm wrong). But corn starch may only be 'miraculous' when compared to mineral oil placebos. In other words corn starch may be truly inert and lets other therapies (statin, diet, etc) be more effective whereas oil placebo masks those effects and gives an artificailly positive effect to the fish oils.

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!